Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

25.99 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

17 18 Next >

Why Are Acadia Pharmaceuticals Shares Trading Higher Today? ↗

July 14, 2023

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher after the company expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American

Via Benzinga

Why Aehr Test Systems Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

July 14, 2023

Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 108.2% to $1.52 in pre-market trading after gaining around 7% on Thursday.

Via Benzinga

Microsoft To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Friday ↗

July 14, 2023

Keybanc boosted the price target for Spotify Technology S.A. (NYSE: SPOT) from $180 to $205. Keybanc analyst Justin Patterson maintained an Overweight rating. Spotify shares rose 0.9% to $172.68 in...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 14, 2023

It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday!

Via InvestorPlace

Where ACADIA Pharmaceuticals Stands With Analysts ↗

July 11, 2023

Via Benzinga

11 Analysts Have This to Say About ACADIA Pharmaceuticals ↗

June 14, 2023

Via Benzinga

Why These 2 Biotech Stocks Made Big Moves Late Thursday ↗

July 13, 2023

Markets kept powering higher on the day.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 13, 2023

Via Benzinga

Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome

July 13, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

June 29, 2023

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

June 14, 2023

Via Benzinga

ACADIA Pharmaceuticals's Return On Capital Employed Insights ↗

May 23, 2023

Via Benzinga

What 22 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗

May 09, 2023

Via Benzinga

ACADIA Pharmaceuticals's Earnings: A Preview ↗

May 05, 2023

Via Benzinga

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Strategic Fit of ACP-101 Promises Future Revenue Growth for Acadia Pharmaceuticals: Analyst ↗

June 14, 2023

Tuesday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for hyperphagia (a false...

Via Benzinga

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome

June 13, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome

June 08, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

3 Penny Stocks That Could Skyrocket in the Next 12 Months ↗

June 07, 2023

Find the top penny stocks to buy, and you can make a fortune. Pick the wrong one and there are also plenty of horrors.

Via InvestorPlace

Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

June 01, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying ↗

May 25, 2023

Although US stocks closed lower on Wednesday, there were a few notable insider trades.

Via Benzinga

ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

May 24, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Records 52-Week High Tuesday Morning

May 23, 2023

Via Investor Brand Network

Top 5 Health Care Stocks That Should Keep You Up At Night ↗

May 23, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview

May 08, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

May 02, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023

April 25, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting

April 20, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher ↗

April 17, 2023

ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else?

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

All News about ACADIA Pharmaceuticals Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today